Using the RBD antigen as bait Premkumar et al. demonstrated sensitivities of 94%, 77.5% and 69% for IgG, IgA and IgM, respectively, in a cohort of 49 samples obtained from COVID-19 patients >9 days after onset of illness [11]. This evidence concerns the gene CD79A and COVID-19.